ProCE Banner Activity

ICARIA-MM: Second Interim Analysis of Phase III Study of Addition of Isatuximab to Pomalidomide and Low-Dose Dexamethasone in R/R Myeloma

Slideset Download
Conference Coverage
Updated results from ICARIA-MM confirm significant PFS benefit and show improvement in time to next therapy with addition of isatuximab to pomalidomide/low-dose dexamethasone in relapsed/refractory myeloma.

Released: June 09, 2021

Expiration: June 08, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme